Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When will tenofovir alafenide come off patent in canada?
Brenzavvy discontinuation?
Symbravo medication information ema europa eu?
What condition primarily benefits from sapropterin therapy?
Pramlintide fda approval date?

What are the latest advancements in tigecycline patent for injection?

See the DrugPatentWatch profile for tigecycline

Recent Patent Filings for Tigecycline Injection

Tigecycline, a glycylcycline antibiotic used for complicated infections, has seen new patent activity focused on injectable formulations. In 2023, Accord Healthcare filed US Patent 11,617,698 for a tigecycline for injection composition with improved stability and reduced degradation, covering lyophilized powders with specific buffers and bulking agents.[1] This builds on earlier patents expiring around 2025-2027, aiming to extend protection amid generic competition.

When Do Original Tigecycline Patents Expire?

The core Tygacil (tigecycline) patents from Wyeth/Pfizer expired in the US by 2022, with pediatric exclusivity ending December 2023. Key formulation patents, like US 6,872,724 for injectable compositions, lapsed in 2022. DrugPatentWatch tracks 15 patents listed for Tygacil, with the last expiring in 2032—mostly method-of-use claims rather than core injection tech.[2] This opens doors for generics, but new secondary patents challenge that timeline.

Generic and Biosimilar Approvals for Injectable Tigecycline

FDA approved the first generic tigecycline for injection in December 2023 from Sandoz, matching Pfizer's Tygacil labeling for IV use in skin, intra-abdominal, and pneumonia infections.[3] Additional ANDAs from Accord, Apotex, and Dr. Reddy's are pending Paragraph IV challenges. No true biosimilars exist, as tigecycline is a small-molecule synthetic antibiotic, not biologic. Europe saw generics launch earlier via EMA in 2022.

Challenges to Tigecycline Injection Patents

Pfizer faces multiple Paragraph IV litigations. In 2023, Apotex challenged US 10,478,451 (a stability patent for injection), settled with a license allowing entry by 2026.[4] Accord's countersuits claim Pfizer's patents are invalid for obviousness in lyophilized formulations. These disputes delay full generic flooding, keeping prices high—branded Tygacil vials cost $1,000+ per treatment course versus generics at 20-30% less.

Formulation Improvements in New Patents

Latest patents emphasize injection-specific tweaks:
- Enhanced solubility via pH-adjusted buffers (e.g., glycine, sodium hydrogen phosphate) to cut reconstitution time.[1]
- Reduced impurities like epimer degradation, critical for hospital IV use.
- A 2024 Chinese patent (CN117018920) covers nanoparticle tigecycline injections for better bioavailability.[5]

These address clinical pain points like slow dissolution in standard 50mg/100mg vials.

Who Makes Tigecycline for Injection Now?

| Manufacturer | Product Status | Key Markets |
|--------------|----------------|-------------|
| Pfizer (Tygacil) | Branded originator | Global |
| Sandoz/Novartis | First US generic (approved Dec 2023) | US, EU |
| Accord Healthcare | ANDA pending; new patent holder | US, India |
| Apotex | Licensed entry 2026 | US, Canada |
| Meitheal Pharmaceuticals | Authorized generic via Pfizer deal | US |

Pricing: Generics dropped US wholesale acquisition cost to ~$200/vial from $1,000.[6]

Supply Issues and Clinical Impact

Tigecycline shortages peaked in 2023 due to manufacturing halts at Pfizer's plants, resolved by mid-2024 with generic ramps.[7] New patents target this by improving shelf-life to 36 months. Clinically, advancements enable outpatient IV use, though resistance concerns persist— tigecycline retains utility against multidrug-resistant Acinetobacter.

[1] US Patent 11,617,698
[2] DrugPatentWatch: Tygacil Patents
[3] FDA Generic Approval Notice
[4] Court Docket: Apotex v. Pfizer
[5] CN Patent 117018920
[6] IQVIA Pricing Data 2024
[7] FDA Drug Shortages List



Other Questions About Tigecycline :

the impact of efflux pumps on the tigecycline-induced resistance Is liver risk with tigecycline higher in elderly or pediatric patients? How does tigecycline s cost impact physician choices? Should transaminase levels be monitored during tigecycline therapy? Is there a link between tigecycline abuse and death? Are certain patient populations more susceptible to liver enzyme elevation during extended tigecycline use? Are there any specific liver function tests that should be performed while on tigecycline?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The provided content does not include any AI-generated response text to evaluate against the supplied FDA-approved prescribing information. Only a set of claims (mostly non-label patent/market/availability statements) and an unrelated/placeholder assessment are given, so no label-adherence assessment can be performed for FDA-approved indication, dosing/administration, contraindications, boxed warnings, warnings/precautions, interactions, populations, or adverse reactions.

Category Scores

Indication
0
Poor
Indication
0
Poor
Indication
0
Poor
Indication
0
Poor

Accurate Statements

Unsupported Statements

Tigecycline is a glycylcycline antibiotic used for complicated infections.
Not evaluable against the supplied prescribing-information excerpts because no FDA-approved indication text (Section 1) beyond limitations is provided, and the claim is not supported by the provided label snippets.
FDA approved the first generic tigecycline for injection in December 2023 from Sandoz.
Not supported by the supplied FDA prescribing information excerpts (Sections provided are limited to Indications/Warnings/Adverse Reactions).
The Sandoz generic tigecycline labeling matches Pfizer's Tygacil labeling for IV use in skin, intra-abdominal, and pneumonia infections.
Not supported by the supplied excerpts; the provided label text includes limitations for pneumonia/diabetic foot infections but does not include full indication language for skin/intra-abdominal/pneumonia or any comparison to Sandoz labeling.
No true biosimilars exist for tigecycline because tigecycline is a small-molecule synthetic antibiotic and not a biologic.
Not supported by the supplied prescribing information excerpts.
Tigecycline shortages peaked in 2023 due to manufacturing halts at Pfizer's plants.
Not supported by the supplied prescribing information excerpts.
Tigecycline retains utility against multidrug-resistant Acinetobacter.
Not supported by the supplied prescribing information excerpts.
The new patents described aim to enable outpatient IV use.
Not supported by the supplied prescribing information excerpts.
Pricing was reported as branded Tygacil vials costing $1,000+ per treatment course, versus generics at 20-30% less.
Not supported by the supplied prescribing information excerpts.

Contradictions

Low

AI Statement
The claim set indicates pneumonia is an approved target (e.g., '... matches ... for IV use in ... pneumonia infections').

Label Reference
Label Section 1.4 Limitations of Use: 'TYGACIL is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia.'

Important Omissions

The actual AI-generated narrative/response text that contains these claims is not provided as a single evaluable answer; only a list of claims and a separate placeholder audit object are provided. Without the exact response text, mapping each statement to label language and assessing full context (including whether statements are quoting/overstating label content) is not possible.
Importance: High

Safety Assessment

Potential Patient Risk: Low
Most statements are non-label (patents, market, shortages, pricing). The only potentially label-relevant item concerns pneumonia; however, full context and whether the claim asserts an indication are not verifiable from the provided material. No direct dosing/contraindication/warnings misuse is evidenced within the provided excerpted label assessment.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Unverifiable Against Supplied Label

Primary Issue
No single AI-generated response text was provided to evaluate; most claims are not label-based and cannot be assessed against the supplied prescribing information excerpts.

Suggested Improvement
Provide the exact AI response text to audit and the complete FDA label sections relevant to the claims (at minimum full Indications and Usage and any sections covering warnings/precautions, adverse reactions, contraindications, and dosage/administration).

Drug Brand Mention Assessment

Branding Score
32
Visibility
42
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

Tigecycline, a glycylcycline antibiotic used for complicated infections

Core Claims
  • Tigecycline is a glycylcycline antibiotic used for complicated infections.
  • New patent activity focuses on injectable formulations.
  • Patents aim to improve stability and reduce degradation for injectable lyophilized powders.
  • Latest patents emphasize injection-specific tweaks like improved solubility via pH-adjusted buffers and reduced impurities.
  • New patents also target shelf-life improvements and relate to supply/shortage dynamics.
Differentiators
  • Improved stability and reduced degradation in injectable formulations.
  • Enhanced solubility via pH-adjusted buffers to reduce reconstitution time.
  • Reduced impurities like epimer degradation for hospital IV use.
  • A nanoparticle formulation patent for better bioavailability.
Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Pfizer 55%
41 #2 No
Sandoz 45%
41 #3 No
Accord 42%
41 #4 No
Apotex 29%
41 #5 No
Novartis 33%
41 #6 No
Meitheal Pharmaceuticals 19%
41 #7 No